The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis.
about
New developments in the management of Waldenström macroglobulinemiaTargeting B Cell Signaling in Chronic Lymphocytic Leukemia.Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.Advances in the treatment of relapsed/refractory chronic lymphocytic leukemiaPractical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2.Profound Sinoatrial Arrest Associated with Ibrutinib.Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials.Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms
P2860
Q34553880-646B4FA1-2829-47F3-AC90-1D425DF60DCCQ38654101-B46FCC17-E492-4023-B2D9-2A622DF13875Q38656503-772F382E-74AD-4363-813B-EAA31E088F6DQ38944823-BCF259B8-4F4B-4439-92BC-1E46648CDAACQ38969861-F31F56F7-C566-4B05-8CF4-5439028DEBBBQ39227773-745FD346-097F-4D70-8554-5439933D0848Q39306435-21DD9AC2-7B41-49BC-9B76-3E1E04C0DFE7Q39325783-F71AB1B8-BDBB-4ABD-9E1F-AFA0749D2EAEQ39383524-3D0E9676-9349-4253-B10A-3F42366CD49CQ42368314-B9411342-B3F3-4447-993F-A486FB829125Q45073137-147753D3-AC72-48BF-B7C0-50A1C93345E0Q47548582-CC4753AC-FB2D-4A69-A5AC-A5D4A9FBBC5FQ47780043-E6CDA636-C026-4D64-8A11-820F94C12EA2Q50121608-C53E24C3-BC61-4DAE-B0F3-9CC80683292EQ50166015-AC264D0D-14AC-4319-8B8E-815A1DD4D79AQ54976521-12DBC5D8-C09A-4518-9CE3-F363565D9B55Q58554222-6F639AE2-7A1A-49CD-9C53-FBD882D976EE
P2860
The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
The risk of atrial fibrillatio ...... atic review and meta-analysis.
@en
The risk of atrial fibrillatio ...... atic review and meta-analysis.
@nl
type
label
The risk of atrial fibrillatio ...... atic review and meta-analysis.
@en
The risk of atrial fibrillatio ...... atic review and meta-analysis.
@nl
prefLabel
The risk of atrial fibrillatio ...... atic review and meta-analysis.
@en
The risk of atrial fibrillatio ...... atic review and meta-analysis.
@nl
P2093
P31
P1433
P1476
The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis
@en
P2093
Annie Duan
Christopher Hillis
Darryl P Leong
François Caron
Graeme Fraser
Jeff S Healey
P304
P356
10.1182/BLOOD-2016-05-712828
P407
P577
2016-05-31T00:00:00Z